Equities research analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to post earnings per share (EPS) of ($0.59) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Aclaris Therapeutics’ earnings. The lowest EPS estimate is ($0.65) and the highest is ($0.54). Aclaris Therapeutics posted earnings of ($1.06) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 44.3%. The business is expected to report its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Aclaris Therapeutics will report full-year earnings of ($2.83) per share for the current fiscal year, with EPS estimates ranging from ($3.24) to ($2.07). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.60) per share, with EPS estimates ranging from ($2.36) to ($0.74). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.05. The firm had revenue of $5.87 million for the quarter, compared to analysts’ expectations of $5.77 million. Aclaris Therapeutics had a negative return on equity of 81.40% and a negative net margin of 979.65%.
Shares of NASDAQ ACRS traded up $0.17 during midday trading on Friday, hitting $1.36. 226,779 shares of the stock traded hands, compared to its average volume of 3,169,801. The firm has a 50-day moving average of $1.13 and a two-hundred day moving average of $3.40. The firm has a market capitalization of $58.33 million, a P/E ratio of -0.34 and a beta of 0.83. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.22 and a current ratio of 3.23. Aclaris Therapeutics has a one year low of $0.74 and a one year high of $13.73.
Several large investors have recently bought and sold shares of ACRS. Aperio Group LLC purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth $33,000. BNP Paribas Arbitrage SA increased its stake in shares of Aclaris Therapeutics by 82,200.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 7,398 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of Aclaris Therapeutics by 66.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 21,200 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 8,500 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Aclaris Therapeutics by 199.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 31,246 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 20,800 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth $69,000. Hedge funds and other institutional investors own 86.10% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Featured Article: What is a CD ladder?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.